MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIV.

ABSTRACT:

Objective

Metabolic dysfunction associated fatty liver disease (MAFLD) is over-represented in people with HIV (PWH). Maraviroc (MVC) and/or metformin (MET) may reduce MAFLD by influencing inflammatory pathways and fatty acid metabolism.

Design

Open-label, 48-week randomized trial with a 2 x 2 factorial design.

Setting

Multicenter HIV clinics.

Participants

Nondiabetic, virologically suppressed PLWH, aged at least 35 years, with confirmed/suspected MAFLD (≥1 biochemical/anthropometric/radiological/histological features).

Intervention

Adjunctive MVC; MET; MVC+MET vs. antiretroviral therapy (ART) alone.

Primary outcome

Change in liver fat fraction (LFF) between baseline and week-48 using magnetic resonance proton density fat fraction (MR PDFF).

Res

SUBMITTER: McCabe L 

PROVIDER: S-EPMC11239089 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature